TLDR:
- Midwest medical firm HistoSonics secures $102m in Series D funding round led by Alpha Wave Ventures.
- The funding will be used to support the development and commercialization of the company’s non-invasive platform for the treatment of solid tumors.
In a recent development, Midwest medical firm HistoSonics has successfully raised $102 million in a Series D funding round, with Alpha Wave Ventures leading the investment. The company plans to utilize the funds to further develop and commercialize its non-invasive platform for the treatment of solid tumors.
HistoSonics is focused on utilizing histotripsy, a technology that uses sound energy to mechanically destroy targeted tissue, to treat a variety of conditions, including prostate cancer, liver cancer, and renal cell carcinoma. The company’s technology has shown promising results in preclinical and clinical studies, positioning it as a potential game-changer in the field of oncology.
The Series D funding round marks a significant milestone for HistoSonics as it continues to advance its innovative approach to cancer treatment. With the substantial financial backing from Alpha Wave Ventures and other investors, the company is well-positioned to accelerate its research and development efforts, ultimately bringing its groundbreaking technology to market.
Overall, the successful fundraising efforts by HistoSonics underscore the growing interest and investment in the healthcare and biotech sectors, particularly in companies that are pioneering new and effective therapies for complex medical conditions like cancer. The infusion of capital will undoubtedly propel HistoSonics towards achieving its mission of revolutionizing cancer treatment and improving outcomes for patients worldwide.
